Clear Search sequence regions
Bookmark Forward

QuickView for Verapamil (compound)


PubChem
Name: Verapamil
PubChem Compound ID: 10072830
Description: A calcium channel blocker that is a class IV anti-arrhythmia agent.
Molecular formula: C27H38N2O4
Molecular weight: 457.62 g/mol
DrugBank
Identification
Name: Verapamil
Name (isomeric): DB00661
Drug Type: small molecule
Description: A calcium channel blocker that is a class IV anti-arrhythmia agent.
Synonyms:
Verapamil [Usan:Ban:Inn]; Verapamilum [INN-Latin]; Verapamil HCl; Verapamilo [INN-Spanish]
Brand: Securon, Vasolan, Apo-Verap, Dignover, Cordilox, Cardibeltin, Drosteakard, Cardiagutt, Calan SR, Isoptin SR, Calan, NU-Verap, Novo-Veramil, Verelan, Univer, Arpamyl, Verelan PM, Verexamil, Isoptimo, Quasar, Dilacoran, Isoptin, Veraptin, Veramex, Geangin, Iproveratril, Veracim, Covera-HS, Berkatens
Brand name mixture: Tarka(trandolapril + verapamil hydrochloride)
Category: Vasodilator Agents, Antiarrhythmic Agents, Calcium Channel Blockers, Anti-Arrhythmia Agents
CAS number: 52-53-9
Pharmacology
Indication: For the treatment of hypertension, angina, and cluster headache prophylaxis.
Pharmacology: Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Mechanism of Action:
Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel su...
show more »
Absorption: 90%
Protein binding: 90%
Route of elimination: Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
Half Life: 2.8-7.4 hours
Toxicity: LD50=8 mg/kg (i.v. in mice)
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid alcohol.
Avoid taking with grapefruit juice.
Avoid excessive quantities of coffee or tea (Caffeine).
Avoid natural licorice.
Take with food.
Drug interaction:
NelfinavirNelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed.
TriazolamVerapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam.
AtazanavirAtazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed.
PhenytoinVerapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed.
ButalbitalButalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.
show more »

Targets


Enzymes


Transporters